Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Regeneron, Amgen and Eylea
Regeneron loses bid to block Amgen's Eylea biosimilar launch in US
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said. The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to block the launch during its appeal of a related decision for Amgen in a patent case in West Virginia.
District Court Denies Regeneron’s Motion For Preliminary Injunction To Block Amgen’s Eylea Biosimilar
On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s (“Regeneron”) motion for
RBC would buy Regeneron on weakness with biosimilar Eylea priced in
RBC Capital notes that it was announced that the Court of Appeals denied Regeneron’s (REGN) motion for an emergency injunction and the
Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said. The U.S. Court of App
5h
Regeneron price target lowered to $1,050 from $1,200 at Wells Fargo
Wells Fargo lowered the firm’s price target on Regeneron (REGN) to $1,050 from $1,200 and keeps an Overweight rating on the shares. Given ...
16h
Regeneron Pharmaceuticals' (NASDAQ:REGN) earnings growth rate lags the 26% CAGR delivered to shareholders
Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) shareholders might be concerned after seeing the share price drop ...
MarketWatch
1d
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors
Shares of
Regeneron
Pharmaceuticals Inc. REGN shed 2.24% to $968.50 Monday, on what proved to be an all-around rough ...
18h
Koss Olinger Consulting LLC Buys 24 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Koss Olinger Consulting LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7 ...
4d
The Regeneron effect
Two billion dollars in investments. 4,500 employees. Regeneron has grown into a major economic engine — and it's now ...
2d
Regeneron announces three-year data for EYLEA HD Injection 8 mg study
Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in ...
BioSpace
8d
Regeneron and Sanofi’s Dupixent Tipped to Dominate COPD Biologics Market
Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into ...
12d
What the Options Market Tells Us About Regeneron Pharmaceuticals
In terms of liquidity and interest, the mean open interest for Regeneron Pharmaceuticals options trades today is 77.14 with a ...
1d
Positive Outlook and Buy Rating for Regeneron Despite Expense Adjustment
Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Regeneron (REGN – Research Report). The associated price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Amgen
NASDAQ
Eylea
Aflibercept
Feedback